| |
|
|
| |
|
| |
ScleroPLUS HP is the most versatile laser system treating leg veins plus other vascular conditions such as; facial spider veins, port wine stains, hemangiomas, rosacea, stretch marks, angiomas, scars and warts. The ScleroPLUS's patented dynamic non-linear exitation enables delivery of LongPulse durations at various wavelengths. The multiple wavelengths allow the physician to control depth of penetration and vessel coagulation. The LongPulse duration results in gentle, uniform heating and coagulation across the entire vessel diameter. The system's multiple handpieces allow more precice treatment of veins and lesions in a wide variety of configurations |
| |
|
| |
Specifications |
Dimensions(HxWxD) |
51.5" x 22" x 37", 131cm x 57cm x 94cm |
Weight |
300 lbs |
Operating Weight |
550 lbs., 250 kg. |
Pulse Characteristics |
Pulse Duration |
1500 microseconds (nominal) |
Pulse Rate |
User-controlled single pulse or repeat mode (up to 1Hz.) |
Spot Sizes |
standard
optional 5,7,2x7mm
2,3,10mm |
Fluence Range |
2x7mm - 30 J/cm2
2,3,5mm - 20 J/cm2
7mm - 15 J/cm2
10mm - 6 J/cm2 |
Beam delivery |
Lens-coupled optical fiber with handpiece |
Pulse Control |
Finger switch / Foot switch |
Laser Type |
Flashlamp excited pulsed dye laser |
Wavelength |
585,590,595,600nm (selectable) |
Aiming Laser |
HeNe Laser (continuous) |
Electrical requirements |
200/208/230 V~, 19A nominal, 50/60 Hz single phase |
U.S. Patents |
4,829,262 5,066,293 5,109,387 5,287,380 5,599,342 |
Optional Dynamic Cooling Device (DCD) Specifications |
Components |
Master control box with control panel, crogen container, DCD handpiece with distance guage |
Cryogen |
HFC 134a |
Compatibility to Laser Handpieces |
5,7mm round and 2x7mm elliptical |
Spray Duration |
User adjustable range: 20-100ms |
Delay Duration |
User adjustable range: 10-500ms |
Control System |
|
Installation Requirements |
By a Candela trained technician |
Compatibility to Laser Systems |
ScleroPLUS, SPTL-1b and other future systems |
|
| |
|
| |
ScleroPLUS Treatment Protocol |
| |
|
| |
- The targeted telangiectasia is covered with 4"x4" hydrogel dressing.
- Energy and Wavelength settings are selected.
- Laser is put into ready mode and handpiece removed from holder.
- Calibration/Verification if necessary.
- Aiming laser (HeNe) is visualized on skin.
- Elliptical Spot is aligned to targeted vessel.
- Footswitch is depressed / Laser pulses are delivered.
- Handpiece is moved to adjacent spot on targeted vessel.
- Footswitch is depressed / Laser pulses are delivered.
- Process is repeated until telangiectasia are fully covered.
- Hydrogel dressing is removed.
- A fresh, cool piece of hydrogel dressing is taped over the treated area.
- Dressing can be removed later by patient.
- Note: The ScleroPLUS induces a very mild purpura after treatment.(much less noticeable than the SPTL lasers)
|
| |
|
| |
Estimated time for average treatment is less than 5 minutes. (Approximately 150 pulses) |
| |
|
| |
ScleroPLUS Clinical Results |
| |
|
| |
The clinical trials have been performed at four sites over the past 8 to 10 months to optimize the treatment. The sites are: |
| |
|
| |
Laser and Skin Surgery Center of NY - Roy Geronemus, Arielle Kavaur, Melanie Grossman |
| |
|
| |
Thomas Jefferson University - Eric Bernstein |
| |
|
| |
UCLA - Department of Dermatology - Gary Lask |
| |
|
| |
RESULTS |
Sclerotherapy |
ScleroPLUS |
Number of Treatments |
1 to 4 |
1 to 2 |
Response Rate |
90% |
92% |
Hyperpigmentation Incidence |
30% |
20% |
Hyperpigmentation Resolution |
80% in 6-24 mo |
80% in < 5 mo. |
Telangiectatic Matting |
35% |
none |
Other Complications |
0.5% |
none |
|
| |
|
| |
These results were from a controlled clinical trial including all above mentioned sites. This data includes treatments on over 60 patients at all four sites. As the clinical study matures, more patients treatments will be administered and further follow up evaluations will be collected. This study will be submitted for publication |
| |
|
|
|
